Literature DB >> 21296778

Incidence, risk factors, and consequences of new-onset atrial fibrillation following epicardial ablation for ventricular tachycardia.

Srijoy Mahapatra1, Damien J LaPar, Castigliano M Bhamidipati, George McDaniel, Sandeep Kamath, T Jared Bunch, Gorav Ailawadi.   

Abstract

INTRODUCTION: We sought to determine the incidence, predictors, and consequences of new-onset atrial fibrillation (AF) following epicardial ventricular tachycardia (VT) ablation. METHODS AND
RESULTS: A total of 41 patients with no prior history of AF underwent epicardial VT ablation via a percutaneous subxiphoid approach. All patients were monitored continuously for 3 days following ablation and then via implantable cardiac defibrillator (ICD) or Holter monitoring. Mean age was 70.0 ± 11.3 years and mean ejection fraction was 30.3 ± 16.6%. In seven (17%) patients, the right ventricle (RV) was punctured during access with subsequent needle withdrawal without requiring surgical repair. Thirty patients (73%) were treated with amiodarone following ablation. Post-ablation, eight (19.5%) patients had documented new-onset AF within 7 days. All AF patients had clinical symptoms of pericarditis. One patient with AF was maintained on amiodarone post-procedure. Complications of AF included three patients who received inappropriate ICD shocks and one patient who developed a large, left atrial appendage clot. Acutely, all patients responded to short-term medical therapy or electrical cardioversion. At 18.0 ± 9.0 months of follow-up, no patient had recurrence of AF, and all were off antiarrhythmic drugs. One patient had typical atrial flutter requiring catheter ablation. Risk factors for AF included lack of amiodarone immediately after ablation (12.5 vs. 87.9%, P < 0.001), RV puncture (50.0 vs. 9.1%, P = 0.02), and epicardial ablation time >10 min (62.5 vs. 3.0%, P < 0.001).
CONCLUSIONS: Atrial fibrillation after epicardial ablation is common and can lead to ICD shocks and atrial thrombus formation. Short-term antiarrhythmic drug therapy and ICD reprogramming should be considered after epicardial VT ablation.

Entities:  

Mesh:

Year:  2011        PMID: 21296778      PMCID: PMC3065918          DOI: 10.1093/europace/eur017

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  22 in total

1.  Site-specific twelve-lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction.

Authors:  Victor Bazan; Edward P Gerstenfeld; Fermin C Garcia; Rupa Bala; Nuria Rivas; Sanjay Dixit; Erica Zado; David J Callans; Francis E Marchlinski
Journal:  Heart Rhythm       Date:  2007-07-14       Impact factor: 6.343

2.  Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis.

Authors:  Kwok M Ho; Jen Aik Tan
Journal:  Circulation       Date:  2009-03-30       Impact factor: 29.690

3.  Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle.

Authors:  Victor Bazan; Rupa Bala; Fermin C Garcia; Jonathan S Sussman; Edward P Gerstenfeld; Sanjay Dixit; David J Callans; Erica Zado; Francis E Marchlinski
Journal:  Heart Rhythm       Date:  2006-07-08       Impact factor: 6.343

4.  The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting.

Authors:  J W Leitch; D Thomson; D K Baird; P J Harris
Journal:  J Thorac Cardiovasc Surg       Date:  1990-09       Impact factor: 5.209

5.  Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial.

Authors:  S Giri; C M White; A B Dunn; K Felton; L Freeman-Bosco; P Reddy; J P Tsikouris; H A Wilcox; J Kluger
Journal:  Lancet       Date:  2001-03-17       Impact factor: 79.321

6.  Impact of prophylactic postoperative beta-blockade on post-cardiothoracic surgery length of stay and atrial fibrillation.

Authors:  Craig I Coleman; Kristen A Perkerson; Effie L Gillespie; Jeffrey Kluger; Robert Gallagher; Sheryl Horowitz; C Michael White
Journal:  Ann Pharmacother       Date:  2004-10-26       Impact factor: 3.154

Review 7.  Transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia.

Authors:  E Sosa; M Scanavacca; A d'Avila
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

8.  Prophylactic catheter ablation for the prevention of defibrillator therapy.

Authors:  Vivek Y Reddy; Matthew R Reynolds; Petr Neuzil; Allison W Richardson; Milos Taborsky; Krit Jongnarangsin; Stepan Kralovec; Lucie Sediva; Jeremy N Ruskin; Mark E Josephson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

9.  Prognostic importance of defibrillator shocks in patients with heart failure.

Authors:  Jeanne E Poole; George W Johnson; Anne S Hellkamp; Jill Anderson; David J Callans; Merritt H Raitt; Ramakota K Reddy; Francis E Marchlinski; Raymond Yee; Thomas Guarnieri; Mario Talajic; David J Wilber; Daniel P Fishbein; Douglas L Packer; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

10.  Experimental efficacy of pericardial instillation of anti-inflammatory agents during percutaneous epicardial catheter ablation to prevent postprocedure pericarditis.

Authors:  Andre d'Avila; Petr Neuzil; Aravinda Thiagalingam; Paulo Gutierrez; Ryan Aleong; Jeremy N Ruskin; Vivek Y Reddy
Journal:  J Cardiovasc Electrophysiol       Date:  2007-09-20
View more
  3 in total

1.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

3.  Significance and clinical characteristics of atrial fibrillation post epicardial access.

Authors:  Alan Sugrue; Ammar M Killu; David O Hodge; Christopher J McLeod; Thomas M Munger; Siva K Mulpuru; Douglas L Packer; Suraj Kapa; Samuel J Asirvatham; Paul A Friedman
Journal:  J Interv Card Electrophysiol       Date:  2016-12-09       Impact factor: 1.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.